CERELA   05438
CENTRO DE REFERENCIA PARA LACTOBACILOS
Unidad Ejecutora - UE
artículos
Título:
Milk fermented with a 15-lipoxygenase-1-producing Lactococcus lactis alleviates symptoms of colitis in a murine model
Autor/es:
T. SARAIVA; K. MORAIS; V. BASTOS PEREIRA; M. DE AZEVEDO; C. SANTOS ROCHAT; C. CASTRO PROSPERI; A.C. GOMES SANTOS; L. BERMUDEZ-HUMARAN; A. CAETANO FARIA; H.M. BLOTTIERE; P. LANGELLA; A. DE MORENO DE LEBLANC; J.G. LEBLANC; V. AZEVEDO
Revista:
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Editorial:
BENTHAM SCIENCE PUBL LTD
Referencias:
Lugar: Oak Park; Año: 2015 vol. 16 p. 424 - 424
ISSN:
1389-2010
Resumen:
Inflammatory bowel diseases (IBD), such as Crohns disease and ulcerative colitis, is characterized by extensive inflammation due to dysregulation of the innate and adaptive immune system whose exact etiology is not yet completely understood. Currently there is no cure for IBD, thus the search for new molecules capable of controlling IBD and their delivery to the site of inflammation are the goal of many researchers. The aim of this work was to evaluate the antiinflammatory effect of the administration of milks fermented by a Lactococcus (L.) lactis strain producing 15-lipoxygenase-1 (15-LOX-1) using a trinitrobenzenesulfonic acid-induced IBD mouse model. The results obtained demonstratedthat 15-LOX-1 producing L. lactis was effective in the prevention of the intestinal damage associated to inflammatory bowel disease in a murine model. The work also confirmed previous studies showing that fermented milk is an effective form of administration of recombinant lactic acid bacteria expressing beneficial molecules.